SHR-1819 Injection
Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions
Adolescents With Moderate-to-severe Atopic DermatitisAtopic DermatitisChildren and Adolescents With Moderate-to-severe Atopic DermatitisModerate to Severe Atopic DermatitisModerate-to-severe Atopic DermatitisPrurigo NodularisSeasonal Allergic Rhinitis
Phase 1
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
CompletedNCT06713499
Start: 2024-12-18End: 2025-11-22Updated: 2026-07-02
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
CompletedNCT07264335
Start: 2026-03-07End: 2026-06-26Updated: 2026-08-24
Phase 2
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
CompletedNCT06012812
Start: 2023-09-06End: 2025-06-05Updated: 2026-03-05
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
RecruitingNCT06554509
Start: 2024-09-19End: 2028-10-01Target: 423Updated: 2026-04-29
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
CompletedNCT07091357
Start: 2025-08-06End: 2025-12-01Updated: 2026-08-27
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
Active, not recruitingNCT07321951
Start: 2026-01-09End: 2027-08-01Updated: 2026-06-04
Phase 3
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
RecruitingNCT07309055
Start: 2026-03-21End: 2027-12-01Target: 201Updated: 2026-09-08
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
RecruitingNCT07688772
Start: 2026-08-11End: 2026-12-01Target: 196Updated: 2026-08-17